[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"proliferative-vitreoretinopathy-in-rhegmatogenous-retinal-detachment\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:proliferative-vitreoretinopathy-in-rhegmatogenous-retinal-detachment":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,44],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100622673","study-of-imaging-and-molecular-biomarkers-in-uncomplicated-rhegmatogenous-retinal-detachment-100622673",false,"NCT07386678","Study of Imaging and Molecular Biomarkers in Uncomplicated Rhegmatogenous Retinal Detachment","Cohort-NHS","Inclusion Criteria:\n\n* Adults ≥18 years\n* Uncomplicated primary rhegmatogenous retinal detachment\n* PVD present\n* No PVR-A\u002FB\u002FC\n* Phakic or pseudophakic.\n\nExclusion Criteria:\n\n* Patients \\\u003C18 years\n* Patients lacking capacity\n* Previous vitrectomy\n* Previous cryopexy\n* Aphakia\n* No fundal view\n* Diabetic retinopathy of any severity\n* Retinal detachment secondary to infective causes e.g. acute retinal necrosis, toxoplasmosis scars\n* Retinal detachment secondary to congenital defects e.g. optic disc pit\u002Fcoloboma\n* Exudative retinal detachment\n* Tractional retinal detachment\n* Ongoing involvement in another ocular trial.","ALL","18 Years",{"count":19,"type":20},50,"ESTIMATED","3 Months","OBSERVATIONAL","Disease or general study area: Uncomplicated rhegmatogenous retinal detachment (RRD) and risk of proliferative vittroretinopathy (PVR)\n\nPurpose and nature of the study:\n\n1. Characterise the cytokine profile of vitreous fluid in uncomplicated RRD.\n2. Develop a risk model to predict development of PVR after retinal detachment surgery using imaging and molecular biomarkers.\n3. To develop deep learning\u002Fartificial intelligence (AI) models for PVR detection in retinal detachment.\n\nInclusion criteria:\n\n50 adult ( ≥18 years) patients with uncomplicated rhegmatogenous retinal detachments without PVR.\n\nWhat participating will involve:\n\nPre- and post-operative assessments and intervention will follow standard of care for patients with rhegmatogenous retinal detachments.\n\nAdditional intervention will include non-invasive imaging of anterior chamber flare, vitreous, wide-field retina, macula optical coherence tomography (OCT) and macula OCT-angiography (OCT-A) as well as, seeking participant's consent on collecting their vitreous fluid at time of their surgery for cytokine analysis.",[25,26,27],"Retinal Detachment Rhegmatogenous","Proliferative Vitreoretinopathy","Proliferative Vitreoretinopathy in Rhegmatogenous Retinal Detachment",[29,30],"Cytokines","Imaging","NOT_YET_RECRUITING","2026-05-05",{"date":34,"type":35},"2026-05-06","ACTUAL",{"date":37,"type":20},"2026-04-27",{"date":39,"type":20},"2027-01-27",{"name":41,"class":42},"University College, London","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":53,"phases":54,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":5},"100479506","phase-2-intravitreal-topotecan-in-the-repair-of-rhegmatogenous-retinal-detachment-with-proliferative-vitreoretinopathy-100479506","NCT05523869","Intravitreal Topotecan in the Repair of Rhegmatogenous Retinal Detachment with Proliferative Vitreoretinopathy","A Prospective Matched Cohort Study of Intravitreal Topotecan in the Repair of Rhegmatogenous Retinal Detachment with Proliferative Vitreoretinopathy","TOPO-RD","To be enrolled, patients need to meet the following inclusion criteria:\n\n1. patients aged 18 years and older\n2. patients who undergo PPV and\u002For SB for recurrent RRD due to PVR\n3. patients with RRD and PVR grade C or D\n4. patients who have failed standard of care surgery for RRD in the same eye previously. In order to satisfy this inclusion criterion, patients need to have previously received at least one vitreoretinal surgery for RRD, including pneumatic retinopexy, pars plana vitrectomy and\u002For scleral buckle, and to have clinical documentation supporting re-detachment of the retina after one or more vitreoretinal surgeries for RRD in the same eye. This cohort of patients is expected to have an extremely guarded visual prognosis and visual potential.\n5. patients who are voluntarily able and willing to participate Patients undergoing combined phacoemulsification and PPV and\u002For SB will also be included. Any surgical technique will be considered, including relaxing retinotomy or retinectomy during PPV.\n\nThe following subject exclusion criteria will be considered:\n\n1. patients with a history of tractional or exudative retinal detachment\n2. patients with severe non-proliferative or proliferative diabetic retinopathy\n3. patients with other planned ocular surgery following PPV\n4. patients with primary RRD\n5. female patients of childbearing age (i.e. less than 50 years old).\n6. patients with pre-existing bone marrow suppression or cytopenias\n7. patients with pre-existing interstitial lung disease (ILD) Any other medications or treatments, including rescue therapy, will be permitted before and\u002For during the trial.",{"count":19,"type":20},"INTERVENTIONAL",[55],"PHASE2","Intravitreal topotecan has anti-inflammatory, anti-proliferative and anti-fibrotic activity that we hypothesize may exhibit high efficacy for the treatment of proliferative vitreoretinopathy (PVR) in patients with rhegmatogenous retinal detachment (RRD). A high efficacy for intravitreal topotecan has been exhibited in cell cultures of PVR. At the same time, intravitreal topotecan has been routinely used in the treatment of vitreous seeds from retinoblastoma. At doses of 5-30 micrograms per injection, no adverse events have been reported with the use of intravitreal topotecan. Therefore, the current prospective matched phase II trial aims to investigate the efficacy and safety of intravitreal topotecan for severe PVR in patients with RRD.",[27],"RECRUITING","2025-02-07",{"date":61,"type":35},"2025-02-11",{"date":63,"type":35},"2023-02-23",{"date":65,"type":20},"2026-02",{"name":67,"class":42},"Unity Health Toronto"]